NCT05169515
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 60 versions: 26 with changes below, 24 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 7 words
- Primary and study completion moved earlier from Aug 5, 2029 to Apr 30, 2029
- Study sites: 25 to 24
- Minor Primary and study completion moved earlier from Sep 15, 2029 to Aug 5, 2029v59
- Minor Enrollment closed, study ongoing
- Study sites: 26 to 25
- Study Status, Contacts/Locations, Referencesv56
- Minor Study sites revised (26)v53
Show 21 earlier versionsHide 21 earlier versions
- Minor Study sites revised (26)v50
- Notable Primary and study completion dates pushed to Sep 15, 2029v48
- Minor Study sites: 27 to 26v38
Notable Primary completion date: Jul 15, 2026 to Mar 7, 2027v37 Show 6 more changesShow less
- Eligibility criteria expanded, about 136 words
- Primary endpoints: 3 to 4
- Study completion date: Jul 15, 2028 to Mar 7, 2029
- Interventions: CC-220 (Drug), CC-99282 (Drug), IV Glofitamab (Drug), Obinutuzumab (Drug), SC Mosunetuzumab (Drug), Tocilizumab (Drug) to Golcadomide (Drug), IV Glofitamab (Drug), Iberdomide (Drug), Obinutuzumab (Drug), SC Mosunetuzumab (Drug), Tocilizumab (Drug)
- Secondary endpoints: 10 to 11
- Study title revised
Notable Primary endpoints: 4 to 3v36 Show 7 more changesShow less
- Eligibility criteria expanded, about 2 words
- Enrollment target: 125 to 121
- Primary completion date: Mar 15, 2027 to Jul 15, 2026
- Study completion date: Mar 15, 2029 to Jul 15, 2028
- Interventions: Golcadomide (Drug), IV Glofitamab (Drug), Iberdomide (Drug), Obinutuzumab (Drug), SC Mosunetuzumab (Drug), Tocilizumab (Drug) to CC-220 (Drug), CC-99282 (Drug), IV Glofitamab (Drug), Obinutuzumab (Drug), SC Mosunetuzumab (Drug), Tocilizumab (Drug)
- Secondary endpoints revised (10)
- Study title revised
Notable Primary completion date: Jul 15, 2026 to Mar 15, 2027v35 Show 7 more changesShow less
- Primary endpoints: 3 to 4
- Eligibility criteria shortened, about 2 words
- Enrollment target: 121 to 125
- Study completion date: Jul 15, 2028 to Mar 15, 2029
- Interventions: CC-220 (Drug), CC-99282 (Drug), IV Glofitamab (Drug), Obinutuzumab (Drug), SC Mosunetuzumab (Drug), Tocilizumab (Drug) to Golcadomide (Drug), IV Glofitamab (Drug), Iberdomide (Drug), Obinutuzumab (Drug), SC Mosunetuzumab (Drug), Tocilizumab (Drug)
- Secondary endpoints revised (10)
- Study title revised
- Minor Site details revised at 1 of 27 sitesv34
- Minor Study sites: 25 to 27v31
- Minor Study sites: 24 to 25v27
- Minor Study sites: 23 to 24v26
- Minor Study sites: 21 to 23v25
- Minor Study sites: 19 to 21v24
- Notable Primary completion date: Apr 15, 2025 to Jul 15, 2026
- Eligibility criteria expanded, about 33 words
- Study completion date: Apr 15, 2027 to Jul 15, 2028
- Secondary endpoints: 21 to 10
- Minor Enrollment target: 112 to 121v21
- Minor Study sites: 18 to 19v20
- Minor Study sites: 17 to 18v18
- Minor Study sites: 14 to 17v17
- Notable Eligibility criteria expanded, about 18 words
- Study sites: 10 to 14
- Minor Study sites: 7 to 10v13
- Minor Study sites: 5 to 7
- Start date changed from estimate of Oct 15, 2022 to Oct 26, 2022
- Notable Start date: Sep 15, 2022 to Oct 15, 2022
- Study sites: 3 to 5
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Percentage of participants with dose-limiting toxicities (DLTs) [dose escalation]
Timeframe: Until 90 days after the final dose of study treatment
Percentage of participants with adverse events [all cohorts]
Timeframe: Until 90 days after the final dose of study treatment
Best overall response rate (ORR), defined as the proportion of participants whose best overall response is a partial response (PR) or a complete response (CR) during the study, as determined by the investigator using Lugano 2014 criteria [dose expansion]
Timeframe: Up to 2 years after start of primary study treatment
Tolerability, as assessed by the incidence of dose interruptions, dose reductions, dose intensity, and treatment discontinuation [dose escalation]
Timeframe: Until 90 days after the final dose of study treatment
Secondary (11)
Best CR rate, defined as the proportion of participants whose best overall response is a CR during the study, as determined by the investigator using Lugano 2014 criteria [all cohorts]
Best ORR (CR or PR at any time) on study as determined by the investigator using Lugano 2014 criteria [dose escalation]
Duration of response (DOR) as determined by the investigator using Lugano 2014 criteria [all cohorts]
Progression-free survival (PFS) as determined by the investigator using Lugano 2014 criteria [dose expansion]
Event-free survival (EFS) as determined by the investigator using Lugano 2014 criteria [dose expansion]
Show 6 moreShow less
Overall survival (OS) [dose expansion]
Percentage of participants with adverse events [dose expansion]
Serum concentration of subcutaneous (SC) mosunetuzumab [all cohorts]
Serum concentration of intravenous (IV) glofitamab [all cohorts]
Serum concentration of CC-220 and CC-99282 (CELMoDs) [all cohorts]
Tolerability, as assessed by the incidence of dose interruptions, dose reductions, dose intensity, and treatment discontinuation [dose expansion]
Arms and interventions
Arm 1Experimental
Participants will receive subcutaneous (SC) mosunetuzumab + CC-220 (dose escalation only) or SC mosunetuzumab + CC-99282.
Arm 2Experimental
Participants will receive intravenous (IV) glofitamab + CC-99282.
Drugs: SC Mosunetuzumab, IV Glofitamab, Iberdomide, Golcadomide, Obinutuzumab, Tocilizumab
Sites
24 sites in 5 countries
Spain 6, United States 6, Israel 5, United Kingdom 4, Italy 3